List of Lupkynis drug patents
Lupkynis is owned by Aurinia.
Lupkynis contains Voclosporin.
Lupkynis has a total of 2 drug patents out of which 0 drug patents have expired.
Lupkynis was authorised for market use on 22 January, 2021.
Lupkynis is available in capsule;oral dosage forms.
Lupkynis can be used as treatment of patients with active lupus nephritis.
Drug patent challenges can be filed against Lupkynis from 2025-01-22.
The generics of Lupkynis are possible to be released after 07 December, 2037.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7332472 | AURINIA | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Oct, 2023
(6 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 2025-01-22
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE;ORAL
LUPKYNIS family patents
43
United States
22
Japan
10
Canada
9
European Union
7
Australia
7
Korea, Republic of
7
China
5
Israel
4
South Africa
4
Denmark
4
Austria
4
Russia
4
Norway
4
Germany
4
Croatia
4
Brazil
4
Portugal
4
Spain
4
Poland
3
Mexico
3
Hong Kong
3
Morocco
3
Colombia
3
Yugoslavia
3
Taiwan, Province of China
3
Ecuador
3
Tunisia
3
New Zealand
2
Slovenia
2
Uruguay
2
Argentina
2
Malaysia
2
ME
1
IB
1
Belgium
1
Lithuania
1
Singapore
1
Chile
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic